Joseph Rabbat, Boyu Yang, Hye Won Lee, Huapeng Lin, Emmanuel Tsochatzis, Salvatore Petta, Elisabetta Bugianesi, Masato Yoneda, Ming-Hua Zheng, Hannes Hagström, Jérôme Boursier, José Luis Calleja, George Boon-Bee Goh, Wah-Kheong Chan, Rocio Gallego-Durán, Arun J. Sanyal, Victor de Lédinghen, Philip N Newsome, Jian-Gao Fan, Laurent Castéra, Michelle Lai, Céline Fournier-Poizat, Grace Lai-Hung Wong, Mirko Zoncape, Grazia Pennisi, Angelo Armandi, Atsushi Nakajima, Wen-Yue Liu, Ying Shang, Marc de Saint-Loup, Elba Llop, Kevin Kim Jun Teh, Carmen Lara-Romero, Amon Asgharpour, Sara Mahgoub, Mandy Sau-Wai Chan, Clemence M Canivet, Manuel Romero-Gomez, Vincent Wai-Sun Wong, Seung Up Kim, Terry Cheuk-Fung Yip
Clin Mol Hepatol 2026;32(1):289-304. Published online November 11, 2025
Background/Aims Current guidelines recommend a 2-step approach for identifying advanced fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD), using Fibrosis-4 index (FIB-4) followed by liver stiffness measurement (LSM) via vibration-controlled transient elastography (VCTE). However, some patients may exhibit discordant results. This study evaluates the histological severity and outcomes in patients with discordant FIB-4 and LSM results.
Methods This secondary analysis of the VCTE-Prognosis study included 12,950 patients evaluated for MASLD at 16 tertiary centers, of whom 2,915 underwent liver biopsy. Patients were categorized into four groups based on established FIB-4 (1.3) and LSM (8 kPa) cutoffs.
Result s: F3–F4 fibrosis was observed in 6.4%, 13.7%, 30.6%, and 62.4% in low-FIB-4-low-LSM (n=6,403), high-FIB-4-low-LSM (n=3,017), low-FIB-4-high-LSM (n=1,363), and high-FIB-4-high-LSM (n=2,167) groups, respectively. During a median follow-up of 47.4 months, 248 patients experienced hepatic decompensation, hepatocellular carcinoma, liver transplantation, or liver-related death. The incidence rates of liver-related events (LREs) were 0.67, 1.19, 2.58, and 21.30 per 1,000 person-years, respectively. Compared to low-FIB-4-low-LSM patients, those with low-FIB-4-high-LSM (adjusted subdistribution hazard ratio [aSHR] 4.12) and high-FIB-4-high-LSM (aSHR 21.38) had a significantly higher risk of LREs, while high-FIB-4-low-LSM patients did not. Similar findings were observed when hepatic decompensation and hepatocellular carcinoma were analyzed separately.
Conclusions Approximately 30% of patients in tertiary centers exhibit discordant FIB-4 and LSM results, with LSM more likely reflecting true severity. While some patients with discordant results may have advanced fibrosis, the overall incidence of LREs remains low.
Background/Aims Metabolic dysfunction-associated steatotic liver disease (MASLD) was recently proposed as an alternative disease concept to nonalcoholic fatty liver disease (NAFLD). We aimed to investigate the prognosis of patients with biopsy-confirmed MASLD using data from a multicenter study.
Methods This was a sub-analysis of the Clinical Outcome Nonalcoholic Fatty Liver Disease (CLIONE) study that included 1,398 patients with NAFLD. Liver biopsy specimens were pathologically diagnosed and histologically scored using the NASH Clinical Research Network system, the FLIP algorithm, and the SAF score. Patients who met at least one cardiometabolic criterion were diagnosed with MASLD.
Result s: Approximately 99% of cases (n=1,381) were classified as MASLD. Patients with no cardiometabolic risk (n=17) had a significantly lower BMI than patients with MASLD (20.9 kg/m2 vs. 28.0 kg/m2, P<0.001), in addition to significantly lower levels of inflammation, ballooning, NAFLD activity score, and fibrosis stage based on liver histology. These 17 patients had a median follow-up of 5.9 years, equivalent to 115 person-years, with no deaths, liver-related events, cardiovascular events, or extrahepatic cancers. The results showed that the prognosis for pure MASLD was similar to that for the original CLIONE cohort, with 47 deaths and one patient who underwent orthotopic liver transplantation. The leading cause of death was extrahepatic cancer (n=10), while the leading causes of liver-related death were liver failure (n=9), hepatocellular carcinoma (n=8), and cholangiocarcinoma (n=4).
Conclusions Approximately 99% of NAFLD cases were considered MASLD based on the 2023 liver disease nomenclature. The NAFLD-only group, which is not encompassed by MASLD, had a relatively mild histopathologic severity and a favorable prognosis. Consequently, the prognosis of MASLD is similar to that previously reported for NAFLD.
Citations
Citations to this article as recorded by
The Bubble-Destruction Curve Obtained Using Contrast-Enhanced Ultrasound is Useful for Assessing Liver Fibrosis and Identifying At-risk MASH in Patients With MASLD Noritaka Wakui, Yu Ogino, Naohisa Kamiyama, Takuma Oguri, Tomoya Uchimura, Takahide Kudo, Kenichi Maruyama, Hideki Nagumo, Naoyuki Yoshimine, Kunihide Mouri, Kojiro Kobayashi, Takanori Mukozu, Teppei Matsui, Hidenari Nagai, Yoshinori Igarashi, Takahisa Ma Ultrasound in Medicine & Biology.2026; 52(1): 237. CrossRef
Ethnic disparities in metabolic dysfunction-associated steatotic liver disease and clinical outcomes Yusuke Miyatani, Aoi Ogawa, Tomoki Sempokuya, Chuong Tran, Davis James, Todd Seto, Cecilia Shikuma, Scott K. Kuwada Frontiers in Endocrinology.2026;[Epub] CrossRef
Measures of comorbid cardiometabolic burden and cardiovascular disease risk in people with MRI-confirmed steatotic liver disease: a prospective cohort study Qi Feng, Pinelopi Manousou, Chioma N. Izzi-Engbeaya, Mark Woodward Cardiovascular Diabetology.2026;[Epub] CrossRef
Multicenter Prospective Cohort Study on Clinical Outcomes and Fibrosis Patterns in Biopsy-Proven Steatotic Liver Disease Subtypes Gi-Ae Kim, Heejoon Jang, Moon Young Kim, Jeong Hwan Park, Jung Gil Park, Eun-Young Cho, Jae Yoon Jeong, Seogsong Jeong, Seul Ki Han, Heesu Kwon, Youngae Jung, Geum-Sook Hwang, Yu Rim Lee, Soo Young Park, Sang Gyune Kim, Won Kim Gastroenterology.2026;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease and risk of four intrahepatic and extrahepatic diseases Yiyuan Xiao, Sihua Xu, Wenyan Hu, Jiapeng Huang, Deke Jiang, Rong Na, Zhaoqing Yin, Jingjing Zhang, Haitao Chen Annals of Hepatology.2025; 30(1): 101750. CrossRef
Alcohol Intake and Cardiometabolic Risk Factors Are Independently Associated With a Higher AST/Platelet Ratio Index in Obese Males Hideki Fujii, Yoshihiro Kamada, Yuichiro Suzuki, Koji Sawada, Miwa Tatsuta, Tatsuji Maeshiro, Hiroshi Tobita, Tsubasa Tsutsumi, Takemi Akahane, Chitomi Hasebe, Miwa Kawanaka, Takaomi Kessoku, Yuichiro Eguchi, Hayashi Syokita, Atsushi Nakajima, Tomoari Kam Liver International Communications.2025;[Epub] CrossRef
Cardiometabolic dysfunction burden and mortality outcomes in metabolic dysfunction-associated steatotic liver disease Ying Wen, Yu Min, Yi Lei, Zhigong Wei, Sophia Eugenia Martínez-Vázquez PLOS One.2025; 20(7): e0327772. CrossRef
The PNPLA3 I148M variant is associated with immune cell infiltration and advanced fibrosis in MASLD: a prospective genotype–phenotype study Jaejun Lee, Jung Hoon Cha, Hee Sun Cho, Keungmo Yang, Hyun Yang, Heechul Nam, Mi Young Byun, Seok Keun Cho, Jinsung Park, Hyuk Wan Ko, Seong Wook Yang, Pil Soo Sung, Si Hyun Bae Journal of Gastroenterology.2025; 60(10): 1284. CrossRef
Effects of laser acupuncture (stress-free therapy) on blood liver function indicators Yoshihiro Kamada, Takunori Sato, Takaomi Kessoku, Yoshio Sumida, Masafumi Ono, Kenji Ryotokuji Laser Therapy.2025;[Epub] CrossRef
Steatotic Liver Disease: A Key Related Risk Factor in the Emergence of Metabolic Syndrome‐Related Disorders Yoshihiro Kamada, Makoto Fujii, Hitoshi Nishizawa, Shiro Fukuda, Makoto Yamada, Iichiro Shimomura, Eiji Miyoshi Hepatology Research.2025;[Epub] CrossRef
Concept, Diagnosis, and Treatment in Steatotic Liver Disease (SLD) Yoshio Sumida, Takaomi Kessoku, Hirotoshi Ebinuma Health Evaluation and Promotion.2025; 52(6): 794. CrossRef
COMBINED DISORDER: CURRENT STATUS OF METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE IN PATIENTS WITH HYPOTHYROIDISM AND PROSPECTS FOR PATIENT PATHWAY IMPLEMENTATION Valentyna Psarova, Anastasiia Cherkashyna Eastern Ukrainian Medical Journal.2025; 13(3): 593. CrossRef
Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences Joo Hyun Oh, Dae Won Jun Clinical and Molecular Hepatology.2024; 30(2): 168. CrossRef
Correspondence on Letter regarding “Prognosis of biopsy-confirmed MASLD: A sub-analysis of the CLIONE study” Hideki Fujii, Michihiro Iwaki, Yoshihiro Kamada Clinical and Molecular Hepatology.2024; 30(2): 281. CrossRef
Usefulness of health checkup‐based indices in identifying metabolic dysfunction‐associated steatotic liver disease Takao Miwa, Satoko Tajirika, Nanako Imamura, Miho Adachi, Ryo Horita, Tatsunori Hanai, Cheng Han Ng, Mohammad Shadab Siddiqui, Taku Fukao, Masahito Shimizu, Mayumi Yamamoto JGH Open.2024;[Epub] CrossRef
Association between nonalcholic fatty liver disease and pancreatic cancer: Epidemiology, mechanisms, and antidiabetic medication Takahiko Sakaue, Hiroya Terabe, Hidetoshi Takedatsu, Takumi Kawaguchi Hepatology Research.2024; 54(8): 729. CrossRef
Reply to correspondence on “Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study” Eileen Laurel Yoon, Dae Won Jun Clinical and Molecular Hepatology.2024; 30(4): 1033. CrossRef
Metabolic-associated fatty liver disease is less effective in predicting mortality than non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease: Letter to the editor on “Prognosis of biopsy-confirmed metabolic dysfun Yixuan Zhu, Xiaoyan Ma, Wenjing Ni, Yee Hui Yeo, Junping Shi, Jie Li Clinical and Molecular Hepatology.2024; 30(4): 974. CrossRef
Sequential Diagnostic Approach Using FIB-4 and ELF for Predicting Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease Yeo-Wool Kang, Yang-Hyun Baek, Sang-Yi Moon Diagnostics.2024; 14(22): 2517. CrossRef
Combi-Elastography versus Transient Elastography for Assessing the Histological Severity of Metabolic Dysfunction-Associated Steatotic Liver Disease Yun Kyu Lee, Dong Hyeon Lee, Sae Kyung Joo, Heejoon Jang, Young Ho So, Siwon Jang, Dong Ho Lee, Jeong Hwan Park, Mee Soo Chang, Won Kim Gut and Liver.2024; 18(6): 1048. CrossRef
Non-alcoholic fatty liver disease is currently the most common chronic liver disease, affecting up to 25% of the global population. Simple fatty liver, in which fat is deposited in the liver without fibrosis, has been regarded as a benign disease in the past, but it is now known to be prognostic. In the future, more emphasis should be placed on the quantification of liver fat. Traditionally, fatty liver has been assessed by histological evaluation, which requires an invasive examination; however, technological innovations have made it possible to evaluate fatty liver by non-invasive imaging methods, such as ultrasonography, computed tomography, and magnetic resonance imaging. In addition, quantitative as well as qualitative measurements for the detection of fatty liver have become available. In this review, we summarize the currently used qualitative evaluations of fatty liver and discuss quantitative evaluations that are expected to further develop in the future.
Citations
Citations to this article as recorded by
Evaluation of thyroid function in patients diagnosed with metabolic dysfunction-associated fatty liver disease: a cross-sectional study Ahmed M. Eldaba, Mona M. Watany, Galal El Din M. Elkassas, Rehab B. El sheshtawy Tanta Medical Journal.2026; 54(1): 143. CrossRef
Circulating hepatocyte-derived extracellular particles as potential biomarker of steatohepatitis progression to fibrogenesis: Exploring the impact of smoking Oumnia Masrour, Justine Morvan, Alison Rapin, Alexis Aimé, Agnès Burel, Valentine Genêt, Stéphanie Brisset, Dominique Lagadic-Gossmann, Edouard Bardou-Jacquet, Corinne Martin-Chouly Digestive and Liver Disease.2026;[Epub] CrossRef
Performance of three clinical scores for steatosis and steatohepatitis and their interaction with metabolic syndrome in obese individuals Giovani Schulte Farina, Bárbara Brambilla, Emanuelle Mendonça Pandolfo, Laura Kalil Nader Lazzaretti, Stéfano Mateus Schio Kuiava, Ana Maria Graciolli, Vitória Maria Kriger, Carlos Henrique Dal Bem Fistarol, Augusto Cardoso Sgarioni, Henrique Prataviera G World Journal of Hepatology.2026;[Epub] CrossRef
Thyroid Stimulating Hormone Levels Are Related to Fatty Liver Indices Independently of Free Thyroxine: A Cross-Sectional Study Federica Sileo, Alessandro Leone, Ramona De Amicis, Andrea Foppiani, Laila Vignati, Francesca Menichetti, Giorgia Pozzi, Simona Bertoli, Alberto Battezzati Journal of Clinical Medicine.2025; 14(7): 2401. CrossRef
The application performance of MRI-PDFF detection values of different hepatic lobes in diagnosing liver steatosis Fengjie Qiao, Yan Xue, Chen Zou, Kun Liu, Jie Yuan, Longshan Ji, Lingying Huang, Man Li, Yueqiu Gao Clinical and Experimental Medicine.2025;[Epub] CrossRef
The value of ultrasonic attenuation parameters and serum indicators on MASLD patients with liver fat degenerationality Yan Liu, Wen Kang, Jingya Su, Yin Yang, Kui Li, Juntao Yang Journal of Radiation Research and Applied Sciences.2025; 18(3): 101647. CrossRef
Quantification of liver steatosis of metabolic dysfunction-associated steatotic liver disease based on body composition analysis Toshikazu Kohira, Satoshi Oeda, Erina Eto, Yoshihito Kubotsu, Misa Norita, Kaori Inoue, Nagisa Hara, Shotaro Noge, Kenichi Tanaka, Shigenobu Yoshimura, Noriko Oza, Keizo Anzai, Yuichiro Eguchi, Cheng Han Ng, Daniel Q. Huang, Mark D. Muthiah, Atsushi Kawag Scientific Reports.2025;[Epub] CrossRef
Discovery of ultrasound-derived fat fraction as a non-invasive tool for MASLD diagnosis Huiru Jin, Mengfan Jiao, Chengxiao Yu, Tingting Ren, Qingling Chen, Zixing Dai, Erfu Xie, Longfeng Jiang, Yuwen Li European Journal of Medical Research.2025;[Epub] CrossRef
Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in
Patients with Non-Alcoholic Fatty Liver Disease: An Updated Systematic Review
and Meta-Analysis of Randomized Controlled Trials Simei Huang, Yu Xi, Yanqing Hong, Chenliang Hu Hormone and Metabolic Research.2025; 57(10): 593. CrossRef
Current Update on Nomenclature, Diagnosis, and Management of Metabolic Dysfunction–associated Steatotic Liver Disease: Radiologists’ Perspective Eri G. Osta, Florentino Saenz Rios, Sriram Jaganathan, Courtney Thomas, Eugenia Tsai, Venkateswar Surabhi, Srinivasa R. Prasad, Venkata S. Katabathina RadioGraphics.2025;[Epub] CrossRef
3D multiparametric ultrasound imaging of steatotic liver disease in a study with male rats Donghyun Lee, Jinseok Heo, Hyeonji Mun, Donghyeon Oh, Yongjoo Ahn, Chulhong Kim Nature Communications.2025;[Epub] CrossRef
Near-Infrared Fluorescent Lipid Droplet Polarity Probe for Distinguishing Different Liver Injury Diseases Xiaodong Tan, Yijia Liu, Siyu Jiang, Zhoupeng Zheng, Guoqiang Feng Chemical & Biomedical Imaging.2025;[Epub] CrossRef
Performance of noninvasive seromarkers in predicting liver fibrosis among MAFLD patients with or without viral hepatitis Chung‐Feng Huang, Po‐Cheng Liang, Chih‐Wen Wang, Tyng‐Yuan Jang, Po‐Yao Hsu, Pei‐Chien Tsai, Yu‐Ju Wei, Ming‐Lun Yeh, Ming‐Yen Hsieh, Yi‐Hung Lin, Chao‐Kuan Huang, Chia‐Yen Dai, Jee‐Fu Huang, Wan‐Long Chuang, Ming‐Lung Yu The Kaohsiung Journal of Medical Sciences.2024; 40(4): 374. CrossRef
Utilizing fully-automated 3D organ segmentation for hepatic steatosis assessment with CT attenuation-based parameters Jeongin Yoo, Ijin Joo, Sun Kyung Jeon, Junghoan Park, Soon Ho Yoon European Radiology.2024; 34(9): 6205. CrossRef
Non–small cell lung cancer and immune checkpoint inhibitor therapy: does non-alcoholic fatty liver disease have an effect? Yi Li, Bingxin Gong, Yusheng Guo, Weiwei Liu, Chao Chen, Shanshan Jiang, Feng Pan, Jiyu Song, Lian Yang, Guofeng Zhou BMC Cancer.2024;[Epub] CrossRef
Head-to-head comparison of three different US-based quantitative parameters for hepatic steatosis assessment: a prospective study Yan Zhou, Mengjin Nie, Hongyu Zhou, Feng Mao, Lin Zhao, Jianmin Ding, Xiang Jing Abdominal Radiology.2024; 49(7): 2262. CrossRef
Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD Farah Abdelhameed, Chris Kite, Lukasz Lagojda, Alexander Dallaway, Kamaljit Kaur Chatha, Surinderjeet S. Chaggar, Maria Dalamaga, Eva Kassi, Ioannis Kyrou, Harpal S. Randeva Current Obesity Reports.2024; 13(3): 510. CrossRef
Maternal obesity and metabolic (dysfunction) associated fatty liver disease in pregnancy: a comprehensive narrative review Bianca M. Leca, Lukasz Lagojda, Chris Kite, Emmanouil Karteris, Eva Kassi, Harpal S. Randeva, Ioannis Kyrou Expert Review of Endocrinology & Metabolism.2024; 19(4): 335. CrossRef
Diagnosis and non‐invasive assessment of MASLD in type 2 diabetes and obesity Wah‐Kheong Chan, Salvatore Petta, Mazen Noureddin, George Boon Bee Goh, Vincent Wai‐Sun Wong Alimentary Pharmacology & Therapeutics.2024;[Epub] CrossRef
This Is What Metabolic Dysfunction–Associated Steatotic Liver Disease Looks Like: Potential of a Multiparametric MRI Protocol Anja M. Fischer, Nazim Lechea, Harvey O. Coxson Seminars in Liver Disease.2024; 44(02): 226. CrossRef
Correspondence to editorial on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis” Hayeon Kim, Min Jeong Park, Myeong Gyu Kim, Kyungim Kim Clinical and Molecular Hepatology.2024; 30(4): 989. CrossRef
From adiposity to steatosis: metabolic dysfunction-associated steatotic liver disease, a hepatic expression of metabolic syndrome – current insights and future directions Bruno Basil, Blessing K. Myke-Mbata, Onyinye E. Eze, Augustine U. Akubue Clinical Diabetes and Endocrinology.2024;[Epub] CrossRef
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future Lynna Alnimer, Mazen Noureddin Clinical and Molecular Hepatology.2023; 29(2): 394. CrossRef
Application of attenuation imaging for the detection of fatty liver in potential liver donors Jae Seok Bae, Dong Ho Lee, Kyung-Suk Suh, Kwang-Woong Lee, Nam-Joon Yi, Suk Kyun Hong European Journal of Radiology.2023; 166: 110958. CrossRef
Editorial: Will MRI‐PDFF become the new standard for steatosis assessment in NAFLD? Angeliki Pappa, Tobias Wenzl Alimentary Pharmacology & Therapeutics.2023; 58(3): 364. CrossRef
Prevalence of Non-Alcoholic Fatty Liver Disease in Adult Individuals with Moderate-to-Severe Atopic Dermatitis Martina Maurelli, Paolo Gisondi, Francesco Bellinato, Alessandro Mantovani, Giovanni Targher, Giampiero Girolomoni Journal of Clinical Medicine.2023; 12(18): 6057. CrossRef
First
Prev
